Could Eledon’s Anti-CD40L Change Transplant Medicine?

 
• By David Wild
Eledon CEO Hopes Tegoprubart Will Be The Cornerstone Of Transplant Immunosuppression • Source: Shutterstock

More from Innovation

More from In Vivo